Latest news with #PEN
Yahoo
12 hours ago
- Business
- Yahoo
3 Reasons to Sell PEN and 1 Stock to Buy Instead
Penumbra currently trades at $256.16 per share and has shown little upside over the past six months, posting a middling return of 4.5%. However, the stock is beating the S&P 500's 1.9% decline during that period. Is now the time to buy Penumbra, or should you be careful about including it in your portfolio? Check out our in-depth research report to see what our analysts have to say, it's free. Even with the strong relative performance, we don't have much confidence in Penumbra. Here are three reasons why we avoid PEN and a stock we'd rather own. Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right. With just $1.24 billion in revenue over the past 12 months, Penumbra is a small company in an industry where scale matters. This makes it difficult to build trust with customers because healthcare is heavily regulated, complex, and resource-intensive. Free cash flow isn't a prominently featured metric in company financials and earnings releases, but we think it's telling because it accounts for all operating and capital expenses, making it tough to manipulate. Cash is king. Penumbra has shown mediocre cash profitability over the last five years, giving the company limited opportunities to return capital to shareholders. Its free cash flow margin averaged 3%, subpar for a healthcare business. Growth gives us insight into a company's long-term potential, but how capital-efficient was that growth? Enter ROIC, a metric showing how much operating profit a company generates relative to the money it has raised (debt and equity). Penumbra's five-year average ROIC was negative 1.4%, meaning management lost money while trying to expand the business. Investors are likely hoping for a change soon. Penumbra isn't a terrible business, but it isn't one of our picks. Following its recent outperformance in a weaker market environment, the stock trades at 64× forward P/E (or $256.16 per share). At this valuation, there's a lot of good news priced in - we think there are better investment opportunities out there. Let us point you toward the Amazon and PayPal of Latin America. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
Yahoo
20-05-2025
- Business
- Yahoo
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry has tumbled by 6.4%. This performance was disappointing since the S&P 500 held its ground. A cautious approach is imperative when dabbling in these businesses as regulation is another unpredictable element that can affect their earnings potential. Taking that into account, here are three healthcare stocks we're swiping left on. Market Cap: $10.87 billion Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE:PEN) develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions. Why Does PEN Fall Short? Modest revenue base of $1.24 billion gives it less fixed cost leverage and fewer distribution channels than larger companies Low free cash flow margin of 3% for the last five years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders Negative returns on capital show that some of its growth strategies have backfired Penumbra is trading at $281.56 per share, or 70.3x forward P/E. Check out our free in-depth research report to learn more about why PEN doesn't pass our bar. Market Cap: $3.33 billion With roots dating back to 1877 when it introduced the first dental electric drill, Dentsply Sirona (NASDAQ:XRAY) manufactures and sells professional dental equipment, technologies, and consumable products used by dentists and specialists worldwide. Why Do We Think XRAY Will Underperform? Weak constant currency growth over the past two years indicates challenges in maintaining its market share Sales were less profitable over the last five years as its earnings per share fell by 7% annually, worse than its revenue declines Waning returns on capital from an already weak starting point displays the inefficacy of management's past and current investment decisions Dentsply Sirona's stock price of $16.72 implies a valuation ratio of 8.8x forward P/E. Dive into our free research report to see why there are better opportunities than XRAY. Market Cap: $868.7 million With a network of thousands of healthcare professionals ranging from nurses to physicians to executives, AMN Healthcare (NYSE:AMN) provides healthcare workforce solutions including temporary staffing, permanent placement, and technology platforms for hospitals and healthcare facilities across the United States. Why Do We Pass on AMN? Declining travelers on assignment over the past two years indicate demand is soft and that the company may need to revise its strategy Sales are expected to decline once again over the next 12 months as it continues working through a challenging demand environment Shrinking returns on capital suggest that increasing competition is eating into the company's profitability At $22.17 per share, AMN Healthcare Services trades at 18.5x forward P/E. If you're considering AMN for your portfolio, see our FREE research report to learn more. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free.
Yahoo
15-05-2025
- Entertainment
- Yahoo
Literary world gathers for PEN America dinner-gala hosted by Amber Ruffin
NEW YORK (AP) — Hundreds of writers, editors and publishers are to gather Thursday night for PEN America's annual gala, hosted by Amber Ruffin and featuring a tribute to actor-publisher Sarah Jessica Parker. Ruffin, the writer-comedian, will have a high-profile platform after she was disinvited from April's White House Correspondents Association dinner. Ruffin is known for her blunt criticism of President Donald Trump, and the WHCA said it wanted the event to focus on journalism. Soon after the association's decision, PEN announced that Ruffin had agreed to preside over its signature event, a dinner-fundraiser held at the American Museum of Natural History. 'She is truly emblematic of the talented creators who we need on stages and in writers' rooms during a time of unprecedented censorship in this country,' PEN co-interim CEO Clarisse Rosaz Shariyf said at the time. PEN itself, the century-old free expression organization, is still recovering from a tumultuous 2024. Allegations that leadership was reluctant to criticize Israel's invasion of Gaza and slow to respond to the suffering of Palestinians, including Palestinian writers and journalists, led so many writers to withdraw from PEN's spring awards ceremony and World Voices festival that both were canceled. PEN CEO Suzanne Nossel departed at the end of the year; a permanent replacement has not yet been announced. The awards night and World Voices returned this month, although with reminders of the ongoing war in Gaza. Several prize nominees withdrew from competition, including two of the five finalists for the $75,000 Jean Stein Book Award for a work of 'originality, merit, and impact.' The daughters of Stein, the late author, editor and philanthropist, decided that the prize money would be donated to the Palestine Children's Relief Fund and to Palestine Legal, a U.S.-based defense organization. On Thursday, PEN will honor the imprisoned Egyptian poet and activist Galal El-Behairy with the PEN/Barbey Freedom to Write Award, given to dissidents who have been jailed. Members of his family will accept the award for him. Parker is to receive the PEN/Audible Literary Service Award, presented in previous years to Patti Smith,Robert Caro and Stephen Sondheim among others. Parker has been a longtime champion of books and literacy and runs the publishing imprint SJP Lit, where authors include Lucy Caldwell, Linda Grant and Elysha Chang. Wesleyan President Michael S. Roth, a leading critic of Trump's threats to cancel research funding at Columbia University and other schools, is this year's winner of the PEN/Benenson Courage Award. PEN is giving its Business Visionary award to Macmillan CEO Jon Yaged.
Winnipeg Free Press
15-05-2025
- Entertainment
- Winnipeg Free Press
Literary world gathers for PEN America dinner-gala hosted by Amber Ruffin
NEW YORK (AP) — Hundreds of writers, editors and publishers are to gather Thursday night for PEN America's annual gala, hosted by Amber Ruffin and featuring a tribute to actor-publisher Sarah Jessica Parker. Ruffin, the writer-comedian, will have a high-profile platform after she was disinvited from April's White House Correspondents Association dinner. Ruffin is known for her blunt criticism of President Donald Trump, and the WHCA said it wanted the event to focus on journalism. Soon after the association's decision, PEN announced that Ruffin had agreed to preside over its signature event, a dinner-fundraiser held at the American Museum of Natural History. 'She is truly emblematic of the talented creators who we need on stages and in writers' rooms during a time of unprecedented censorship in this country,' PEN co-interim CEO Clarisse Rosaz Shariyf said at the time. PEN itself, the century-old free expression organization, is still recovering from a tumultuous 2024. Allegations that leadership was reluctant to criticize Israel's invasion of Gaza and slow to respond to the suffering of Palestinians, including Palestinian writers and journalists, led so many writers to withdraw from PEN's spring awards ceremony and World Voices festival that both were canceled. PEN CEO Suzanne Nossel departed at the end of the year; a permanent replacement has not yet been announced. The awards night and World Voices returned this month, although with reminders of the ongoing war in Gaza. Several prize nominees withdrew from competition, including two of the five finalists for the $75,000 Jean Stein Book Award for a work of 'originality, merit, and impact.' The daughters of Stein, the late author, editor and philanthropist, decided that the prize money would be donated to the Palestine Children's Relief Fund and to Palestine Legal, a U.S.-based defense organization. On Thursday, PEN will honor the imprisoned Egyptian poet and activist Galal El-Behairy with the PEN/Barbey Freedom to Write Award, given to dissidents who have been jailed. Members of his family will accept the award for him. Winnipeg Jets Game Days On Winnipeg Jets game days, hockey writers Mike McIntyre and Ken Wiebe send news, notes and quotes from the morning skate, as well as injury updates and lineup decisions. Arrives a few hours prior to puck drop. Parker is to receive the PEN/Audible Literary Service Award, presented in previous years to Patti Smith, Robert Caro and Stephen Sondheim among others. Parker has been a longtime champion of books and literacy and runs the publishing imprint SJP Lit, where authors include Lucy Caldwell, Linda Grant and Elysha Chang. Wesleyan President Michael S. Roth, a leading critic of Trump's threats to cancel research funding at Columbia University and other schools, is this year's winner of the PEN/Benenson Courage Award. PEN is giving its Business Visionary award to Macmillan CEO Jon Yaged.
Yahoo
12-05-2025
- Health
- Yahoo
Improved Survival and Growth While Cutting Malnutrition for Premature Infants Fed Human Milk-Based Fortifiers at Sydney Hospital
Study Demonstrates Multiple Benefits of Prolacta's Exclusive Human Milk Diet Compared to Traditional Cow Milk-Based Feeding Protocol ADELAIDE, Australia, May 13, 2025 /PRNewswire/ -- Prolacta Bioscience®, the world's leading hospital provider of 100% human milk-based nutritional products, today announced results from an interim analysis of the Personalised Enteral Nutrition (PEN) Study demonstrating the benefits of an Exclusive Human Milk Diet (EHMD) for extremely low birth weight (ELBW) infants. Reduced rates of mortality, improved growth across multiple measurement methods, and reduced malnutrition were some of the findings of using human milk-based products when compared to cow milk-based products. The findings, presented as three posters at the Australian and New Zealand Neonatal Network (ANZNN) Clinical Practice Improvement Conference and the Perinatal Society of Australia and New Zealand (PSANZ) Conference, add to a growing body of research showing the lifesaving potential of Prolacta's Humavant® 100% human milk-based fortifiers and follow the recent introduction of the products across New South Wales, Queensland, and South Australia.1,2,3 Conducted at the Royal Hospital for Women in Sydney, the study evaluated outcomes among ELBW infants (<1000 g) who received either Prolacta's human milk-based fortifiers or a standard feeding protocol with cow milk-based fortifiers until they reached 34 weeks corrected gestational age (CGA). Key findings from the three PEN Study analysis posters: Poster 1 Decreased incidence of malnutrition at 34 weeks CGA from 88% in the control group (n = 17) to 39% in the EHMD group (n = 18)1 Decreased mild malnutrition incidence from 35% in the control group to 28% in the EHMD group (p = 0.90) Reduced rate of moderate-to-severe malnutrition from 53% in the control group to 11% in the EHMD group (p<0.05)1 No cases of necrotizing enterocolitis (NEC), a serious intestinal disease, in the EHMD group compared to 11% in the control group1 Poster 2 Better weight gain in the EHMD group (n = 21), with mean weight increasing by 620 g (±222 g) by day 42 compared to 469 g (±154 g) in the control group (n = 18) (p = 0.017)2 Higher mean head circumference in the EHMD group, increasing by 3.54 cm (±2.57 cm) by day 42 compared to 2.46 cm (±1.26 cm) in infants in the control group (p = 0.11)2 100% survival rate and no occurrence of NEC in the EHMD group2 No deaths due to late-onset sepsis in the EHMD group compared to 11% mortality in infants receiving cow milk-based fortifiers2 Poster 3 Earlier commencement of fortification in the EHMD group: 10.4 days vs. 20.8 days in the control group (p < 0.01)3 Earlier attainment of full enteral feeds of 150 mL/kg/day in the EHMD group: 12.7 days vs. 20.2 days in the control group (p < 0.01)3 Reduced duration of parenteral nutrition in the EHMD group: 12.8 days vs. 20.3 days (p < 0.05)3 Smaller decline in weight z-scores (-0.9 vs -1.6, p < 0.05) and head circumference z-scores (-0.9 vs -1.6) from birth to 36 weeks CGA in the EHMD group3 About an Exclusive Human Milk Diet Humavant fortifiers are the first and only human milk-based products available to hospitals in various regions of Australia as an alternative to cow milk-based nutritional fortifiers for babies born prematurely. Royal Hospital for Women is the first to publish data on its clinical experience using Humavant fortifiers as a part of an EHMD protocol. An EHMD is achieved when 100% of the protein, fat, and carbohydrate in an infant's diet are derived from human milk, including Prolacta's Humavant fortifiers. Human milk nutrition is vital for the health and development of babies born prematurely. Given the estimated 20%–40% increase in caloric needs compared to full-term infants,4 a nutritional fortifier is often added to mum's own milk or donor breast milk to provide the nutritional support that is essential to premature infants' survival, growth, and development. Additionally, a recent study found that the use of a human milk diet with human milk-based fortifiers reduced mortality by 50% compared to a diet with cow milk-based fortifiers.5 Additional information can be found at About Prolacta Bioscience Prolacta Bioscience® is a global life sciences company dedicated to Advancing the Science of Human Milk® to improve health outcomes for critically ill and premature infants. More than 100,000 extremely premature infants6 worldwide have benefited from Prolacta's human milk-based products, which have been evaluated in more than 30 peer-reviewed clinical studies. Operating the world's first pharmaceutical-grade human milk processing facilities, Prolacta maintains the industry's strictest quality and safety standards, with over 20 validated tests for screening and testing human milk. Prolacta's manufacturing process uses vat pasteurization to ensure pathogen inactivation while protecting nutritional composition and bioactivity. Learn more at on X, Instagram, Facebook, TikTok, and LinkedIn. Media Contact: Loren Kosmont Lkosmont@ References Parmar T, Allworth S, Tapawan S, Lui K, Schindler T, Bolisetty S. Weight z-score changes with exclusive human milk diet in the extremely low birth weight infants – an interim subgroup analysis of prospective observational study. Poster presented at: Australian and New Zealand Neonatal Network Clinical Practice Improvement Conference (ANZNN); Oct. 21, 2024; Sydney, Australia. Parmar T, Tapawan SJ, Allworth S, et al. Growth trajectory of preterm infants ≤1000g on an exclusive human milk diet – first Australian experience: an interim subgroup analysis of the personalised enteral nutrition (PEN) study. Poster presented at: Australian and New Zealand Neonatal Network Clinical Practice Improvement Conference (ANZNN); Oct. 21, 2024; Sydney, Australia. Parmar T, Tapawan SJ, Allworth S, et al. Impact of standardised nutrition bundle with exclusive human milk diet on anthropometric z-score trends in preterm neonates <1000g: interim analysis of personalised enteral nutrition (PEN) study. Poster presented at: Australian and New Zealand Neonatal Network Clinical Practice Improvement Conference (ANZNN); Oct. 21, 2024; Sydney, Australia. Hair AB, Bergner EM, Lee ML, et al. Premature infants 750-1,250 g birth weight supplemented with a novel human milk-derived cream are discharged sooner. Breastfeed Med. 2016;11(3):133-137. doi:10.1089/bfm.2015.0166 Galis R, Trif P, Mudura D, Mazela J, Daly MC, Kramer BW, Diggikar S. Association of fortification with human milk versus bovine milk-based fortifiers on short-term outcomes in preterm infants—a meta-analysis. Nutrients. 2024;16:910. 10.3390/nu16060910 Data on file; estimated number of premature infants fed Prolacta's products from January 2007 to August 2023. Logo - View original content: SOURCE Prolacta Bioscience Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
